Publications
-
The interaction between equipoise and logistics in clinical trials: A case study
Citation: Warshaw MG, Carey VJ, McFarland EJ, Dawson L, Abrams E, Melvin A, Fairlie L, Spiegel H, Jay J, Agwu AL; IMPAACT P1094 Team. The interaction between equipoise and logistics in clinical trials: A case study. Clin Trials. 2017 Jun;14(3):314-318. doi: 10.1177/1740774517690734. Epub 2017 Jan 31. PMID: 28135804; PMCID: PMC5446272
Date: 01/31/2017
Phase 2 study of the safety and tolerability of maraviroc-containing regimens to prevent HIV
Citation: Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico KR, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, McGowan I, Cottle LM, Andrade A, Marcus C, Klingman KL, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Magnus M, Farley JE, Liu A, Frank I, Ho K, Santana J, Stekler JD, McCauley M, Mayer KH. Phase 2 study of the safety and tolerability of maraviroc-containing regimens to prevent HIV infection in men who have sex with men (MSM) (HPTN 069/ACTG A5305). J Infect Dis. 2017 Jan 15;215(2):238-246. doi: 10.1093/infdis/jiw525. PMID: 27811319. PMCID: PMC5790146.
Date: 01/15/2017
A medical care missed opportunity: Preexposure prophylaxis and young black men who have sex with men
Citation: Arrington-Sanders R, Morgan A, Oidtman J, Qian I, Celentano D, Beyrer C. A medical care missed opportunity: Preexposure prophylaxis and young black men who have sex with men. J Adolesc Health. 2016 Dec;59(6):725-728. doi: 10.1016/j.jadohealth.2016.08.006. PMID: 27720357; PMCID: PMC5123899
Date: 12/01/2016
Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1
Citation: Kelesidis T, Tran TTT, Brown TT, Moser C, Ribaudo HJ, Dubé MP, Murphy RL, Yang O, McComsey GA, Stein JH, Currier JS. Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection. AIDS. 2016 Nov 13;30(17):2625-2633. PMID: 27603288. PMCID: PMC5083154.
Date: 11/13/2016
Benefits and risks of antiretroviral therapy for perinatal HIV prevention
Citation: Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, McIntyre J, Gnanashanmugam D, Siberry GK, Coletti AS, Taha TE, Klingman KL, Martinson FE, Owor M, Violari A, Moodley D, Theron GB, Bhosale R, Bobat R, Chi BH, Strehlau R, Mlay P, Loftis AJ, Browning R, Fenton T, Purdue L, Basar M, Shapiro DE, Mofenson LM; IMPAACT 1077BF/1077FF PROMISE Study Team. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016 Nov 3;375(18):1726-1737. PMID: 27806243; PMCID: PMC5214343
Date: 11/03/2016
Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL
Citation: Funderburg NT, Xu D, Playford MP, Joshi AA, Andrade A, Kuritzkes DR, Lederman MM, Mehta NN. Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity. Antivir Ther. 2017;22(1):71-75. doi: 10.3851/IMP3091. Epub 2016 Oct 14. PMID: 27740536; PMCID: PMC5516727
Date: 10/14/2016
Sex-related differences in inflammatory and immune activation markers before and after combined
Citation: Mathad JS, Gupte N, Balagopal A, Asmuth D, Hakim J, Santos B, Riviere C, Hosseinipour M, Sugandhavesa P, Infante R, Pillay S, Cardoso SW, Mwelase N, Pawar J, Berendes S, Kumarasamy N, Andrade BB, Campbell TB, Currier JS, Cohn SE, Gupta A; New Work Concept Sheet 319 and AIDS Clinical Trials Group A5175 (PEARLS) Study Teams. Sex-related differences in inflammatory and immune activation markers before and after combined. J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):123-9. doi: 10.1097/QAI.0000000000001095. PMID: 27258230. PMCID: PMC5023467.
Date: 10/01/2016
Neurocognition with maraviroc compared with tenofovir in HIV
Citation: Robertson KR, Miyahara S, Lee A, Brown TT, Chan ES, Berzins B, Rusin D, Eron JJ, Taiwo BO, AIDS Clinical Trials Group (ACTG) 5303 Team. Neurocognition with maraviroc compared with tenofovir in HIV. AIDS. 2016 Sep 24;30(15):2315-21. PMID: 27333088. PMCID: PMC5014739.
Date: 09/24/2016
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-,
Citation: Kelesidis T, Tran TTT, Brown TT, Moser C, Ribaudo HJ, Dubé MP, Murphy RL, Yang O, McComsey GA, Stein JH, Currier JS. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s. Antivir Ther. 2017;22(2):113-126. doi: 10.3851/IMP3093. Epub 2016 Sep 23. PMID: 27661466. PMCID: PMC5364070.
Date: 09/23/2016
Changes in markers of T-cell senescence and exhaustion with atazanavir-, raltegravir-, and
Citation: Kelesidis T, Tran TTT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dubé MP, Murphy RL, Yang O, Currier JS, McComsey GA. Changes in markers of T-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based iinitial antiviral therapy: ACTG 5260s. J Infect Dis. 2016 Sep 1;214(5):748-52. doi: 10.1093/infdis/jiw253. PMID: 27354367. PMCID: PMC4978379.
Date: 09/01/2016
- ‹ First < 10 11 12 13 14 > Last ›